Surmodics Inc. (SRDX)
35.53
-0.31 (-0.86%)
At close: Jan 14, 2025, 3:59 PM
35.55
0.06%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 14.3 |
| Market Cap | 507.87M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -46.75 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 43 |
| Volume | 522,136 |
| Avg. Volume (20D) | 217,455 |
| Open | 35.73 |
| Previous Close | 35.84 |
| Day's Range | 34.76 - 35.94 |
| 52-Week Range | 25.17 - 42.44 |
| Beta | undefined |
About SRDX
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliver...
Industry Medical - Devices
Sector Healthcare
IPO Date Mar 4, 1998
Employees 376
Stock Exchange NASDAQ
Ticker Symbol SRDX
Website https://www.surmodics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for SRDX stock is "Hold." The 12-month stock price forecast is $43, which is an increase of 21.02% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Surmodics Inc. is scheduled to release its earnings on Jan 30, 2025,
before market opens.
Analysts project revenue of $33.37M, reflecting a 9.22% YoY growth and earnings per share of -0.12.
Analysts project revenue of $33.37M, reflecting a 9.22% YoY growth and earnings per share of -0.12.
7 months ago ·
Source
+19.94%
Surmodics shares are trading higher after the comp...
Unlock content with
Pro Subscription
8 months ago ·
Source
+29.74%
Surmodics shares are trading higher following a Q2 earnings beat.
